003120.KO · Ilsung Pharmaceuticals Co., Ltd

-

Please sign in to comment on 003120.KO

1 Comment

Admin

4 years ago

Ilsung Pharmaceuticals Co., Ltd is currently in a long term uptrend where the price is trading 2.8% above its 200 day moving average.

From a valuation standpoint, the stock is 63.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.1.

Ilsung Pharmaceuticals Co., Ltd's total revenue sank by 21.1% to $10B since the same quarter in the previous year.

Its net income has dropped by 38.4% to $2B since the same quarter in the previous year.

Finally, its free cash flow fell by 847.7% to $-6B since the same quarter in the previous year.

Based on the above factors, Ilsung Pharmaceuticals Co., Ltd gets an overall score of 2/5.

Exchange	KO
CurrencyCode	KRW
ISIN	KR7003120003
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

Market Cap	108B
PE Ratio	None
Target Price	None
Dividend Yield	6.3%
Beta	-0.35

ABOUT

Ilsung Pharmaceuticals Co., Ltd

Ilsung Is Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, digestive system medicines, anti-virals, anti-emetics, respiratory treatments, adrenal cortical steroids, anesthetics, antipyretics, and cardiovascular system products. The company was formerly known as Ilsung Pharmaceuticals Co., Ltd. and changed its name to Ilsung Is Co., Ltd. in April 2024. Ilsung Is Co., Ltd. was founded in 1954 and is headquartered in Seoul, South Korea.

003120.KO · Ilsung Pharmaceuticals Co., Ltd

-

Ilsung Pharmaceuticals Co., Ltd

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Ilsung Pharmaceuticals Co., Ltd using a moving average strategy